Last reviewed · How we verify
Henagliflozein and Metformin
Henagliflozein and Metformin is a Small molecule drug developed by Zhujiang Hospital. It is currently FDA-approved.
Henagliflozein and Metformin, marketed by Zhujiang Hospital, is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk is the loss of exclusivity post-2028, which could significantly impact revenue.
At a glance
| Generic name | Henagliflozein and Metformin |
|---|---|
| Sponsor | Zhujiang Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD (PHASE4)
- Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Henagliflozein and Metformin CI brief — competitive landscape report
- Henagliflozein and Metformin updates RSS · CI watch RSS
- Zhujiang Hospital portfolio CI
Frequently asked questions about Henagliflozein and Metformin
What is Henagliflozein and Metformin?
Who makes Henagliflozein and Metformin?
What development phase is Henagliflozein and Metformin in?
Related
- Manufacturer: Zhujiang Hospital — full pipeline
- Compare: Henagliflozein and Metformin vs similar drugs
- Pricing: Henagliflozein and Metformin cost, discount & access